<DOC>
	<DOCNO>NCT00382993</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , crossover , two-attack , out-patient , early-intervention evaluation subject migraine without aura discontinue use short act triptan ( ) within past year due non-response intolerance . Subjects treat 2 separate migraine attack mild phase attack ; one attack treat one tablet Combination Product ( sumatriptan succinate naproxen sodium ) attack one tablet placebo ( crossover design ) . [ Study 2 2 ]</brief_summary>
	<brief_title>A Study Combination Product ( Sumatriptan Succinate Naproxen Sodium ) Migraine Subjects Who Report Poor Response Intolerance Short Acting Triptans ( Study 2 2 )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , crossover , two-attack , out-patient , early-intervention evaluation subject migraine without aura discontinue use short act triptan ( ) within past year due non-response intolerance . Subjects treat 2 separate migraine attack mild phase attack ; one attack treat one tablet Combination Product ( sumatriptan succinate naproxen sodium ) attack one tablet placebo ( crossover design ) ; however , order treatment randomize . A minimum 1-week washout period require study medication treatment first second migraine attack . Each subject two visit : ( 1 ) Screening visit study entry ( 2 ) Final visit 4-10 day second ( last ) attack . A telephone contact also require 1-3 day first attack , per month Final visit . The primary study objective ass efficacy measure sustain pain-free ( SPF ) relief Combination Product compare placebo treat migraine subject previously discontinue treatment short acting triptans ( rizatriptan , sumatriptan , almotriptan , zolmitriptan , eletriptan ) .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject male female 18 65 year old . Subject migraine without aura ( 2004 ICHDII criterion ) . Subject 18 migraine per month previous 3 month le 15 total headache day per month . Subject recently ( within 1 year ) discontinue use eletriptan , rizatriptan , sumatriptan , almotriptan , zolmitriptan , due nonresponse intolerable adverse event . Nonresponse define documented discontinuation treatment eletriptan , rizatriptan , sumatriptan , almotriptan , zolmitriptan reason relate response , include ( limited ) : slow onset efficacy , inconsistent efficacy , inadequate overall efficacy , inadequate sustain efficacy 24 hour . Intolerance define documented discontinuation treatment eletriptan , rizatriptan , sumatriptan , almotriptan , zolmitriptan reason , attributable triptan , outside nonresponse . A female eligible enter participate study : nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; , childbearing potential , negative urine pregnancy test screen , agree one follow acceptable measure contraception : Complete abstinence intercourse 2 week prior administration investigational product , throughout study , time interval completion premature discontinuation study account elimination investigational drug ( minimum 5 day ) ; subject utilizing method must agree use alternate method contraception become sexually active query whether abstinent precede 2 week present clinic Final Visit ; , Female sterilization ; , Sterilization male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combine progestogen ) ; , Any intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Spermicide plus mechanical barrier ( e.g. , spermicide plus male condom female diaphragm ) ; , Any method publish data show high expected failure rate method le 1 % per year ; , Any barrier method use combination acceptable method . Subject take oral contraceptive stable regimen least 2 month prior screen . Subject willing able provide inform consent prior entry treatment phase study . Subject able understand complete diary card . Subjects follow criterion may enroll study : Subject nonmigraine headache , retinal migraine , basilar hemiplegic migraine , cluster headache , headache secondary trauma , cranial cervical disorder , infection , alteration homeostasis , ENT disorder , psychiatric disorder cranial neuralgia . Subject confirm suspected ischemic heart disease ( angina pectoris , history myocardial infarction , document silent ischemia ) , Prinzmetal 's angina/coronary vasospasm , signs/symptoms consistent . Subject evidence history ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome . Subject cardiac arrhythmia require medication history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study . Subject history cerebrovascular pathology include stroke and/or transient ischemic attack ( TIAs ) . Subject history congenital heart disease . Subject uncontrolled hypertension screening ( sit systolic pressure ≥140mmHg , diastolic pressure ≥90mmHg ) . Subject , investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease ( base history presence risk factor include limited , hypertension , hypercholesterolemia , smoker , obesity , diabetes , strong family history coronary artery disease , female surgical physiological menopause , male 40 year age ) . Subject history epilepsy structural brain lesion lower convulsive threshold treat antiepileptic drug seizure control within 5 year prior screen . Subject history impair hepatic renal function , investigator 's opinion , contraindicate participation study . Subject currently take monoamine oxidase inhibitor ( MAOI ) , take MAOI within 2 week prior screen plan take within 2 week treatment . Subject currently take , take previous three month , migraine prophylactic medication contain methysergide dihydroergotamine ; take medication stabilize ( i.e . change dose within past 2 month ) either chronic intermittent migraine prophylaxis comorbid condition stabilized.. Subject currently take anticoagulant ( e.g. , warfarin ) . Subject recent history regular use opioids barbiturates treatment migraine headache and/or nonmigraine pain . Regular use define average 4 day per month last 6 month . Subject currently take take previous 4 week , herbal preparation contain St. John 's Wort ( Hypericum perforatum ) . Subject hypersensitivity , intolerance , contraindication use sumatriptan naproxen sodium component 5HT1 receptor agonist . Subject history allergic reaction naproxen preparation , include subject aspirin NSAID drug induce syndrome asthma , rhinitis , nasal polyp . Subject history gastrointestinal surgery specifically indicate past history bleeding , ulceration perforation . Subject history gastric bypass stapling surgery . Subject history GI ulceration past six month gastrointestinal bleeding past year . Subject history inflammatory bowel disease . Subject history bleeding disorder . Subject take antiplatelet agent ( except lowdose aspirin ≤ 325mg/day cardioprotective reason ) . Subject take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker . Subject pregnant , actively try become pregnant breastfeeding . Subject evidence alcohol substance abuse within last year , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result . Subject concurrent medical psychiatric condition , investigator 's opinion , may affect interpretation efficacy safety data otherwise contraindicate participation clinical trial . Subject participate investigational drug trial within previous four week plan participate another study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>migraine without aura</keyword>
	<keyword>naproxen sodium</keyword>
	<keyword>combination product</keyword>
	<keyword>sumatriptan succinate</keyword>
	<keyword>poor response</keyword>
	<keyword>short act triptan</keyword>
	<keyword>migraine , acute</keyword>
</DOC>